Table 1. Achievement of MR^4.5 according to response status at baseline and crossover.

	Nilotinib arm	Imatinib arm	P-valuea
All patients	n=104	n=103
Achieved MR4.5 by 48 months
ITT, n (%)	56 (53.8)	46 (44.7)	0.1766
Up to crossover, n (%)	56 (53.8)	33 (32.0)	0.0011
After crossover, n/m (%)b	NA	20/46 (43.5)c	NA
Patients without MMR at baseline	n=24	n=28
Achieved MR4.5 by 48 months
ITT, n (%)	8 (33.3)	6 (21.4)	0.4279
Up to crossover, n (%)	8 (33.3)	1 (3.6)	0.0055
After crossover, n/m (%)d	NA	5/17 (29.4)e	NA
Patients with MMR but without MR4.5 at baseline	n=74	n=68
Achieved MR4.5 by 48 months
ITT, n (%)	43 (58.1)	34 (50.0)	0.2273
Up to crossover, n (%)	43 (58.1)	26 (38.2)	0.0084
After crossover, n/m (%)f	NA	14/28 (50.0)g	NA

Abbreviations: ITT, intention-to-treat; MMR, major molecular response; MR^4.5, BCR-ABL1 ⩽0.0032% on the International Scale.

^aP-values are nominal. No multiplicity adjustments were made; therefore, statistical interpretation should be made with caution. P-values were obtained using the Cochran–Mantel–Haenszel test.

^bDenominator is the number of patients who crossed over.

^cA total of 20 patients achieved MR^4.5 after crossover, including 13 who achieved MR^4.5 for the first time on nilotinib, 4 who achieved MR^4.5 on imatinib and maintained the response on nilotinib and 3 who regained MR^4.5 on nilotinib after losing the response prior to crossover.

^dDenominator is the number of patients without MMR at baseline who crossed over.

^eOf the 11 patients without MMR at baseline who did not crossover, 1 achieved MR^4.5 on imatinib and was not eligible to crossover; the other 10 patients were eligible to crossover but did not, and none of these achieved MR^4.5.

^fDenominator is the number of patients with MMR but without MR^4.5 at baseline who crossed over.

^gOf the 68 patients with MMR but without MR^4.5 at baseline, 28 crossed over and 40 did not crossover. Twenty of the 40 patients who did not crossover achieved MR^4.5 on imatinib by the end of the study. Fourteen of the 28 patients who crossed over achieved MR^4.5 by the end of the study, including 10 patients who achieved MR^4.5 for the first time after crossover and 4 patients who achieved MR^4.5 before and after crossover.